Patents by Inventor E. Dale Lehman

E. Dale Lehman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthetic HPV6/11 hybrid L1 DNA encoding human papillomavirus type 11 L1 protein
    Patent number: 6159729
    Abstract: The present invention is directed to a synthetic DNA molecule encoding purified human papillomavirus type 11 L1 protein and derivatives thereof.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: December 12, 2000
    Assignee: Merck & Co., Ltd.
    Inventors: Kathryn J. Hofmann, Kathrin U. Jansen, Michael P. Neeper, Joseph G. Joyce, Hugh A. George, E. Dale Lehman
  • Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
    Patent number: 5821087
    Abstract: The present invention is directed to a recombinant human papillomavirus type 11 L1 protein encoded by a synthetic DNA molecule and methods of making and using the protein.
    Type: Grant
    Filed: September 11, 1996
    Date of Patent: October 13, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Robert Lowe, Joseph G. Joyce, Hugh A. George, Kathryn J. Hofmann, Kathrin U. Jansen, E. Dale Lehman, Michael P. Neeper
  • Purification of hepatitis pre-S antigens by polymerized serum albumin affinity binding
    Patent number: 4742158
    Abstract: Recombinant pre-S-HBsAg is purified by a rapid and efficient two step chromatographic process. Yeast cells expressing recobinant pre-S-HBsAg are disrupted, the cell contents are clarified and separated by polymerized human serum albumin affinity chromatography. The pre-S-HBsAg is further purified by hydrophobic interaction chromatography using butyl agarose. This process results in pre-S-HBsAg that is greater than 90% pure.
    Type: Grant
    Filed: April 14, 1987
    Date of Patent: May 3, 1988
    Assignee: Merck & Co., Inc.
    Inventors: E. Dale Lehman, Ted F. Schaefer, William J. McAleer
  • Immunogenic HbsAg derived from transformed yeast
    Patent number: 4707542
    Abstract: The surface antigen protein of human Hepatitis B virus is synthesized in Saccharomyces cerevisiae as a 23,000-26,000 dalton polypeptide, essentially free of intermolecular disulfide bonds. This antigen is a poor immunogen in animals and man. No prior precedent or method exists for efficiently converting the non-disulfide bonded antigen to a fully intermolecular disulfide bonded particle. We describe the first example of such a conversion in vitro and show that the act of this conversion enhances the immunogenicity of the antigen about 10-fold. The in vitro conversion makes practical the production of hepatitis B surface antigen from microorganisms using recombinant DNA methods.
    Type: Grant
    Filed: August 1, 1984
    Date of Patent: November 17, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Arthur Friedman, E. Dale Lehman, William J. McAleer, Ted F. Schaefer, Edward M. Scolnick, D. Eugene Wampler
  • Herpes subunit vaccine
    Patent number: 4452734
    Abstract: Herpes virus subunit antigens suitable for vaccine use are prepared by (1) treating virus-infected cells with a surfactant and varying concentrations of salt to extract and solubilize viral-directed glycoproteins, (2) fractionating the solubilized material by chromatographic procedures to enrich the viral-directed glycoproteins and to remove unwanted proteins and nucleic acids, and (3) optionally treating the subunit antigens with deoxyribonuclease and formaldehyde to assure safety.
    Type: Grant
    Filed: August 11, 1982
    Date of Patent: June 5, 1984
    Assignee: Merck & Co., Inc.
    Inventors: Vivian M. Larson, E. Dale Lehman
  • Herpes sub unit vaccine
    Patent number: 4374127
    Abstract: Herpes virus subunit antigens suitable for vaccine use are prepared by (1) treating virus-infected cells with a surfactant and varying concentrations of salt to extract and solubilize viral-directed glycoproteins, (2) fractionating the solubilized material by chromatographic procedures to enrich the viral-directed glycoproteins and to remove unwanted proteins and nucleic acids, and (3) optionally treating the subunit antigens with deoxyribonuclease and formaldehyde to assure safety.
    Type: Grant
    Filed: February 11, 1980
    Date of Patent: February 15, 1983
    Assignee: Merck & Co., Inc.
    Inventors: Vivian M. Larson, E. Dale Lehman